Article: Seguimiento de guías farmacoterapéuticas en mayores de 85 años con insuficiencia cardiaca estadio C. Efecto sobre la mortalidad al año.
Revista espanola de geriatria y gerontologia
2009 Volume 44, Issue 2, Page(s) 90–93
Abstract: Objective: To describe factors related to prescription on discharge of treatment for Chronic Heart Failure(CHF)-Stage C and to analyse whether this is related to 12month-mortality.: Material and methods: Observational follow-up study of patients over ...
Title translation | Adherence to pharmaceutical guidance in patients over 85 years of age with chronic heart failure-stage C. Effects on 12-month mortality. |
---|---|
Abstract | Objective: To describe factors related to prescription on discharge of treatment for Chronic Heart Failure(CHF)-Stage C and to analyse whether this is related to 12month-mortality. Material and methods: Observational follow-up study of patients over 85 hospitalized during 2006/7 with Stage C-Chronic Heart Failure in an outskirt support hospital. Drug-prescription adherence was assessed according to the American Heart Society 2005-Guidelines and recommendations of the American Geriatrics Society-2007. A multivariate analysis of logistic regression was performed to obtain odds for 12-month mortality for each recommended therapy, adjusting by mortality risk factors. Results: 104 patients aged 90+/-3yr were followed on discharge, 85% of which were women. NYHA-classes were distributed NYHA I-28,2%, II-37,9%, III-30,1%, IV-3,9%. Most frequently prescribed drugs were loop diuretics (83,3%) and IACEs/ARB (62%), and the less frequent beta-blockers (19,1%). IACEs/ARB were prescribed to those with lower functional impairment (p=0.04), and beta-blockers to those with worse NYHA class (p=0.02). All recommended prescriptions had a tendency to 12 month mortality risk reduction, even adjusted by age, functional status, co-morbidity, NYHA class and co-morbid atrial fibrillation, except for spironolactone (OR-1,8; IC95% 0,48-17,19). Conclusions: Treatment with CHF disease-modifying therapies except for spironolactone can reduce 12 month risk mortality, also in the oldest old. There exists room for improvement in frequency of drug prescription in this group of age. |
MeSH term(s) | Aged, 80 and over ; Chronic Disease ; Disease Progression ; Female ; Follow-Up Studies ; Guideline Adherence/statistics & numerical data ; Heart Failure/drug therapy ; Heart Failure/mortality ; Humans ; Male ; Prospective Studies ; Time Factors |
Language | Spanish |
Publishing date | 2009-03 |
Publishing country | Spain |
Document type | English Abstract ; Journal Article |
ZDB-ID | 605609-x |
ISSN | 1578-1747 ; 0211-139X |
ISSN (online) | 1578-1747 |
ISSN | 0211-139X |
DOI | 10.1016/j.regg.2008.10.004 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 2677: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.